EXSCIENTIA
Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their... knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
EXSCIENTIA
Industry:
Artificial Intelligence Biotechnology Health Care Pharmaceutical
Founded:
2012-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.exscientia.ai
Total Employee:
101+
Status:
Active
Contact:
+44-1865-818941
Total Funding:
474.37 M USD
Technology used in webpage:
SPF Domain Not Resolving Amazon Google Apps For Business Microsoft Azure DNS GoDaddy DNS Pound Sterling Amazon S3 CDN Japanese Yen Amazon Ireland Region
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Board_member
Board_member
2020-05-01
Current Employees Featured
Andrew Hopkins Co-Founder and CEO @ Exscientia
Co-Founder and CEO
Adrian Schreyer Chief Technology Officer @ Exscientia
Chief Technology Officer
2018-08-01
Willem van Hoorn Chief Decision Scientist @ Exscientia
Chief Decision Scientist
David Hallett Chief Operating Officer @ Exscientia
Chief Operating Officer
2020-01-01
Michael Krams Chief Quantitative Medicine Officer @ Exscientia
Chief Quantitative Medicine Officer
2022-04-01
Daniel Crowther Chief Bioinformatician @ Exscientia
Chief Bioinformatician
Jeremy Besnard Chief Designer @ Exscientia
Chief Designer
Thorsten Nowak VP Medicinal Chemistry @ Exscientia
VP Medicinal Chemistry
2020-11-01
Richard Bickerton Chief Informatics Officer @ Exscientia
Chief Informatics Officer
2012-10-01
Mark Swindells Chief Commercial Officer @ Exscientia
Chief Commercial Officer
2014-06-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-15 | Allcyte | Allcyte acquired by Exscientia | 50 M EUR |
| 2018-11-15 | Kinetic Discovery Ltd. | Kinetic Discovery Ltd. acquired by Exscientia | N/A |
Investors List
Sanofi
Sanofi investment in Post-IPO Equity - Exscientia
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Exscientia
Hongyou Investment
Hongyou Investment investment in Series D - Exscientia
GT Healthcare Capital Partners
GT Healthcare Capital Partners investment in Series D - Exscientia
Novo Holdings
Novo Holdings investment in Series D - Exscientia
Marshall Wace
Marshall Wace investment in Series D - Exscientia
BlackRock
BlackRock investment in Series D - Exscientia
Bristol Myers Squibb
Bristol Myers Squibb investment in Series D - Exscientia
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series D - Exscientia
SoftBank Vision Fund
SoftBank Vision Fund investment in Series D - Exscientia
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-05 | Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer |
| 2022-01-19 | Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI |
| 2021-10-01 | Exscientia debuts IPO |
Official Site Inspections
http://www.exscientia.ai Semrush global rank: 1.37 M Semrush visits lastest month: 21.06 K
- Host name: 83-223-102-104.as29017.net
- IP address: 83.223.102.104
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
Cannot get whois informations of this domain!!!
More informations about "Exscientia"
Exscientia | Technology-driven AI Drug …
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. At Exscientia, we combine the power of AI …See details»
Exscientia - Crunchbase Company Profile & Funding
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments.See details»
Exscientia - Investor Relations
Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of …See details»
Exscientia - Exscientia Launches AWS AI-powered Platform to …
Jul 10, 2024 OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud …See details»
Exscientia - Recursion and Exscientia, two leaders in the AI drug ...
Nov 20, 2024 Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 …See details»
Recursion, Exscientia, and AI drug discovery’s moment …
4 days ago Recently, two leading and long-established firms in the expanding AI drug discovery sector revealed an unexpected merger. In an approximate 75-25 agreement, Recursion Bio and Exscientia are set to ...See details»
Recursion, Exscientia Merge to Create AI-Enabled …
Aug 8, 2024 The AI-enabled biotechs Recursion and Exscientia have entered into a merger that will create a company with $850 million in cash and 10 upcoming clinical readouts over the next 18 months, according to Thursday’s …See details»
After a tough year, Exscientia folds into Recursion
Aug 8, 2024 The deal caps off a tumultuous year for Exscientia, which uses AI to aid drug discovery. The company racked up Big Pharma partnerships in its early years, including GSK, Bristol Myers Squibb and ...See details»
Patient-first AI - Exscientia
Exscientia’s team is delivering key advances across data acquisition, machine learning and generative systems to fulfil sophisticated design objectives. AI Platforms Talented teams define projects and set strategic goals, while …See details»
Exscientia scored the largest AI deal with a Big Pharma …
Mar 4, 2022 The deal, with its potential value of $5.2 billion, represents the deepest investment by a big pharma company in AI to date. But Exscientia has plenty of other milestones it wants to conquer with AI in the years ahead. In a …See details»
EXSCIENTIA AI LIMITED - Companies House
Filing history for EXSCIENTIA AI LIMITED (SC428761) People for EXSCIENTIA AI LIMITED (SC428761) Registers for EXSCIENTIA AI LIMITED (SC428761) More for EXSCIENTIA AI …See details»
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By ...
1 hour ago Like other AI drug discovery engines, Exscientia’s AI uses large datasets to design compounds that can treat diseases and helps select the right patients for each treatment. By …See details»
Exscientia Uses Generative AI to Reimagine Drug Discovery
Exscientia uses generative artificial intelligence (AI) throughout the design-make-test-learn (DMTL) cycle to discover new therapies for patients quickly and relatively inexpensively. …See details»
AI Drug Discovery Startups: Analysis of Exscientia's Acquisition by ...
1 day ago A European player looking to make a difference in the high growth AI-drug discovery market is Exscientia. Like others in the industry, it too has had an interesting story. After a brief …See details»
Exscientia - Exscientia Appoints New Leaders to Strengthen the …
Jun 6, 2024 About Exscientia. Exscientia is an AI-driven precision medicine company committed to discovering, designing, and developing the best possible drugs in the fastest and most …See details»
Exscientia - Bill & Melinda Gates Foundation
Exscientia plc, an AI-driven pharmaceutical company, is discovering, designing, and developing drugs quickly and efficiently, with three AI-designed drugs in Phase 1 human clinical trials. The …See details»
Exscientia (EXAI): AI Drug Discovery Growth and Stock Outlook
Oct 13, 2024 Focusing on the rapid evolution of AI technology and its impact on the stock market, this report provides an in-depth look at Exencia's (EXAI) company profile, business …See details»
Recursion and Exscientia, two leaders in the AI drug discovery
Nov 20, 2024 --The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly …See details»
NVIDIA and IQVIA Build Domain-Expert Agentic AI for Healthcare …
5 days ago IQVIA, the world’s leading provider of clinical research services, commercial insights and healthcare intelligence, is working with NVIDIA to build custom foundation models and …See details»
Exscientia - Exscientia Builds Automated Laboratories in Oxford to ...
Aug 4, 2021 Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are …See details»